Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of [¹⁴C]Purinostat Mesylate in Healthy Participants
NCT07809217Phase 1Not yet recruiting
- Sponsor
- Zenitar
- Start
- Sep 2026
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of purinostat in cancer, sponsored by Zenitar. Primary endpoint: Cumulative excretion rate of total radioactivity in urine and feces at 216 hours. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
purinostat
03
Conditions
cancer
Beyond the preview
Go deeper on NCT07809217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07809217.